title: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
abstract: Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P<0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P=0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P<0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P<0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.
authors: Department of Oncology, Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Medical School of Nanjing University, Nanjing 210008, China.
authors: J
authors: J
authors: Wei
authors: Z
authors: Z
authors: Zou
authors: X
authors: X
authors: Qian
authors: Y
authors: Y
authors: Ding
authors: L
authors: L
authors: Xie
authors: J J
authors: JJ
authors: Sanchez
authors: Y
authors: Y
authors: Zhao
authors: J
authors: J
authors: Feng
authors: Y
authors: Y
authors: Ling
authors: Y
authors: Y
authors: Liu
authors: L
authors: L
authors: Yu
authors: R
authors: R
authors: Rosell
authors: B
authors: B
authors: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D013940:Thymidylate Synthase / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D002955:Leucovorin; D005472:Fluorouracil